<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain</journal-id><journal-id journal-id-type="iso-abbrev">Brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-id journal-id-type="hwp">brain</journal-id><journal-title-group><journal-title>Brain</journal-title></journal-title-group><issn pub-type="ppub">0006-8950</issn><issn pub-type="epub">1460-2156</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4407186</article-id><article-id pub-id-type="doi">10.1093/brain/awu309</article-id><article-id pub-id-type="publisher-id">awu309</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letters to the Editor</subject></subj-group></article-categories><title-group><article-title>Reply: Parkinson&#x02019;s disease in GTP cyclohydrolase 1 mutation carriers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mencacci</surname><given-names>Niccolo E.</given-names></name><xref ref-type="aff" rid="awu309-AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="awu309-AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pittman</surname><given-names>Alan M.</given-names></name><xref ref-type="aff" rid="awu309-AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="awu309-AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Isaias</surname><given-names>Ioannis U.</given-names></name><xref ref-type="aff" rid="awu309-AFF4"><sup>4</sup></xref><xref ref-type="aff" rid="awu309-AFF5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hardy</surname><given-names>John</given-names></name><xref ref-type="aff" rid="awu309-AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="awu309-AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Klebe</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="awu309-AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhatia</surname><given-names>Kailash P.</given-names></name><xref ref-type="aff" rid="awu309-AFF6"><sup>6</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wood</surname><given-names>Nicholas W.</given-names></name><xref ref-type="aff" rid="awu309-AFF1"><sup>1</sup></xref></contrib><aff id="awu309-AFF1">1 Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1N 3BG, UK</aff><aff id="awu309-AFF2">2 IRCCS Istituto Auxologico Italiano, Department of Neurology and Laboratory of Neuroscience &#x02013; Department of Pathophysiology and Transplantation, &#x02018;Dino Ferrari&#x02019; Centre, Universita` degli Studi di Milano, 20149 Milan, Italy</aff><aff id="awu309-AFF3">3 Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London WC1N 3BG, UK</aff><aff id="awu309-AFF4">4 Department of Neurology, University Hospital, 97080 W&#x000fc;rzburg, Germany</aff><aff id="awu309-AFF5">5 Parkinson Institute, Istituti Clinici di Perfezionamento, 20126 Milan, Italy</aff><aff id="awu309-AFF6">6 Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London WC1N 3BG, UK</aff></contrib-group><author-notes><corresp>Correspondence to: Professor Nicholas W. Wood, Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, WC1N 3BG London, UK E-mail: <email>n.wood@ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>11</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>138</volume><issue>5</issue><fpage>e352</fpage><lpage>e352</lpage><permissions><copyright-statement>&#x000a9; The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/" license-type="creative-commons"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><counts><page-count count="3"/></counts></article-meta></front><body><p>Sir,</p><p>Thank you for the opportunity to reply to the correspondence concerning our recent publication in <italic>Brain</italic>, &#x02018;Parkinson&#x02019;s disease in GTP cyclohydrolase 1 mutation carriers&#x02019; (<xref rid="awu309-B9" ref-type="bibr">Mencacci <italic>et al.</italic>, 2014</xref>). We read with great interest these letters and we thank the authors for their insights.</p><p><xref rid="awu309-B20" ref-type="bibr">Guella <italic>et al.</italic> (2014)</xref> report the screening of <italic>GCH1</italic> in 528 Canadian cases with Parkinson&#x02019;s disease and atypical parkinsonism and 290 matched controls. They identified two variants, the known pathogenic p.K224R (&#x000d7;2) and the novel variant p.A99D (likely pathogenic according to <italic>in silico</italic> prediction tools and interspecies conservation) in three unrelated cases with Parkinsons&#x02019;s disease and the two benign variants p.P23L and p.P69L in one single control individual. The mutational frequency, excluding the aforementioned benign variants, was 0.56% (3/528) in cases versus 0% (0/290) in controls, consistent with the frequency we observed in our study (0.75% in cases versus 0.1% in controls).</p><p>This result is relevant as it represents the first independent confirmation that rare deleterious <italic>GCH1</italic> variants are enriched in patients with Parkinson&#x02019;s disease compared to control subjects. Furthermore, they describe the post-mortem findings of one of the mutated patients, who presented at the age of 82 with DOPA-responsive asymmetric rest tremor. This showed a combination of brainstem Lewy body pathology together with the presence of tau-immunoreactive neurofibrillary tangles. To date, the only available brain pathology analysis of a <italic>GCH1</italic>-associated neurodegenerative parkinsonism case showed severe nigral neurodegeneration and Lewy bodies in surviving nigral cells and in the locus coeruleus (<xref rid="awu309-B5" ref-type="bibr">Gibb <italic>et al.</italic>, 1991</xref>; <xref rid="awu309-B15" ref-type="bibr">Segawa <italic>et al.</italic>, 2004</xref>). Further studies are needed to establish if the tauopathy described by <xref rid="awu309-B20" ref-type="bibr">Guella <italic>et al.</italic> (2014)</xref> in their case represents simply an incidental finding.</p><p>The finding that <italic>GCH1</italic> loss-of-function variants are not only responsible for childhood-onset DOPA-responsive dystonia, but are also associated with adult-onset neurodegenerative parkinsonism, is strengthened by the recent identification, through the meta-analysis of genome-wide association studies (GWAS) data deriving from &#x0223c;13 000 cases and 95 000 controls, that <italic>GCH1</italic> is also a low-risk susceptibility locus for Parkinson&#x02019;s disease (<xref rid="awu309-B10" ref-type="bibr">Nalls <italic>et al.</italic>, 2014</xref>). This finding potentially extends the role of GTP cyclohydrolase 1 (GCH1) deficiency in the pathogenesis of Parkinson&#x02019;s disease beyond carriers of rare deleterious coding mutations.</p><p>The causal link between GCH1 and Parkinson&#x02019;s disease remains a matter of speculation. <xref rid="awu309-B18" ref-type="bibr">Ryan <italic>et al.</italic> (2014)</xref> expand the discussion of our manuscript and add insight into the possible pathogenic mechanisms that predispose <italic>GCH1</italic> loss-of-function mutation carriers to nigrostriatal degeneration.</p><p>In our paper we proposed various hypotheses whereby GCH1 and BH<sub>4</sub> deficiency and consequent chronic reduction of dopamine levels may predispose carriers of <italic>GCH1</italic> mutations to nigral cell degeneration.</p><p><xref rid="awu309-B12" ref-type="bibr">Ryan <italic>et al.</italic> (2014)</xref> point out that different cellular mechanisms secondary to BH<sub>4</sub> deficiency, other than reduced dopamine levels, could contribute to the death of nigral dopaminergic neurons. BH<sub>4</sub> acts as an antioxidant itself and is an essential cofactor for nitric oxide synthases (NOS) activity. Furthermore decreased BH<sub>4</sub> levels have been demonstrated to lead to NOS uncoupling, which results in increased oxidative and nitrative stress (<xref rid="awu309-B3" ref-type="bibr">Chen <italic>et al.</italic>, 2014</xref>). The authors previously described that a haplotype of three SNPs (rs8007267, rs3783641 and rs10483639) at the <italic>GCH1</italic> genomic locus influences plasma GCH1 activity and BH<sub>4</sub> levels (<xref rid="awu309-B2" ref-type="bibr">Antoniades <italic>et al.</italic>, 2008</xref>) and identified BH<sub>4</sub> as a vascular defence mechanism against inflammation-induced endothelial dysfunction (<xref rid="awu309-B1" ref-type="bibr">Antoniades <italic>et al.</italic>, 2011</xref>). Consequently the authors propose that a link between BH<sub>4</sub> levels, oxidative stress, and neuroinflammation could represent the mechanism underlying <italic>GCH1-</italic>associated Parkinson&#x02019;s disease.</p><p>Fitting well with this model, and possibly supporting Ryan <italic>et al.</italic>&#x02019;s view, we found that the <italic>GCH1</italic> SNP (rs11158026), recently identified as a risk variant for Parkinson&#x02019;s disease (<xref rid="awu309-B10" ref-type="bibr">Nalls <italic>et al.</italic>, 2014</xref>), is in moderate linkage disequilibrium (r<sup>2</sup> 0.457; D&#x02019; 0.932) with the SNPs constituting the functional haplotype. This possibly suggests a potential functional basis for the association of this variant to Parkinson&#x02019;s disease.</p><p>The authors have also demonstrated the existence of an interaction between &#x003b1;-synuclein, mitochondrial function and GCH1 activity. Their work may support the compelling hypothesis that a pathogenic cascade occurs in nigral neurons, whereby increased levels of &#x003b1;-synuclein and mitochondrial dysfunction lead to decreased GCH1 activity and BH<sub>4</sub> levels, which in turn may result in increased oxidative stress and cell death (<xref rid="awu309-B12" ref-type="bibr">Ryan <italic>et al.</italic>, 2014</xref>).</p><p>We believe that one of the outstanding questions is whether patients with DOPA-responsive dystonia eventually develop nigral neurodegeneration, or whether neurodegeneration can be avoided by dopaminergic replacement therapy. Answering this question will help to understand to what extent low dopamine levels play a role in nigral cell death, with obvious therapeutic implications for asymptomatic carriers of pathogenic variants.</p><p>Dopaminergic imaging studies performed in a few cases with classic DOPA-responsive dystonia (mostly genetically not confirmed) have shown no evidence of reduced nigrostriatal innervation (<xref rid="awu309-B16" ref-type="bibr">Snow <italic>et al.</italic>, 1993</xref>; <xref rid="awu309-B7" ref-type="bibr">Jeon <italic>et al.</italic>, 1998</xref>). This is consistent with post-mortem analysis of four extra cases showing normal nigral cell count (<xref rid="awu309-B4" ref-type="bibr">Furukawa <italic>et al.</italic>, 1999</xref>; <xref rid="awu309-B6" ref-type="bibr">Grotzsch <italic>et al.</italic>, 2002</xref>; <xref rid="awu309-B14" ref-type="bibr">Segawa <italic>et al.</italic>, 2013</xref>). However, <xref rid="awu309-B13" ref-type="bibr">Sawle <italic>et al.</italic> (1991)</xref> report that six cases with DOPA-responsive dystonia displayed modest but significant reduction in the uptake of <sup>18</sup>F-fluorodopa into both caudates and putamen. Furthermore, <xref rid="awu309-B17" ref-type="bibr">Tadic <italic>et al.</italic> (2012)</xref> report that in DOPA-responsive dystonia cases parkinsonian signs are a relatively common residual motor sign following treatment, possibly suggesting underlying neurodegeneration.</p><p>With regards to this, the case report of <xref rid="awu309-B21" ref-type="bibr">Terbeek <italic>et al.</italic> (2014)</xref> is of great interest. They describe a 41-year-old patient carrying a known pathogenic <italic>GCH1</italic> variant (p.Y75S) with onset of classic DOPA-responsive dystonia at age 11. He was treated with <sc>l</sc>-DOPA (300 mg/day) from the age of 20 with good and sustained response. At age 41, because of rapid recurrence of dystonia after skipping a <sc>l</sc>-DOPA dose, dopaminergic imaging (<sup>123</sup>I-FP-CIT SPECT) was performed and showed severe bilateral and asymmetric reduction of putaminal tracer uptake, a pattern typical of idiopathic Parkinson&#x02019;s disease. However, clinical examination, performed after withdrawing <sc>l</sc>-DOPA, revealed purely dystonic features without any obvious sign of parkinsonism.</p><p>In agreement with the interpretation of <xref rid="awu309-B21" ref-type="bibr">Terbeek <italic>et al.</italic> (2014)</xref>, we believe that this case may indeed represent a case with overlapping DOPA-responsive dystonia and asymptomatic, as yet, nigrostriatal degeneration, possibly arguing against a neuroprotective role of dopamine replacement in <italic>GCH1</italic> mutation carriers.</p><p>Lastly, with regards to the letter by <xref rid="awu309-B19" ref-type="bibr">Furukawa and Kish (2014)</xref>, we agree it is not easy to reconcile the evidence of nigral neurodegeneration that we and others have demonstrated in several individuals with <italic>GCH1</italic>-related parkinsonsim and the intact dopaminergic innervation showed in some other cases (<xref rid="awu309-B11" ref-type="bibr">Nygaard <italic>et al.</italic>, 1992</xref>; <xref rid="awu309-B8" ref-type="bibr">Kang <italic>et al.</italic>, 2004</xref>).</p><p>However, the phenotype of these latter cases, characterized by excellent and prolonged response to very small doses of <sc>l</sc>-DOPA and no motor fluctuations or dyskinesias in spite of decades of treatment, is very different from what we observed in the &#x02018;neurodegenerative&#x02019; cases. It is therefore possible that there may exist two different types of adult-onset parkinsonism associated with <italic>GCH1</italic> mutations; on one side, a benign non-degenerative form, part of the phenotypic spectrum of metabolic GCH1-related striatal dopamine deficiency; on the other, a progressive form of parkinsonism with underlying nigral degeneration.</p><p>In conclusion, we anticipate that post-mortem analysis and longitudinal clinical, neuroimaging, and metabolic studies of larger series of <italic>GCH1</italic> mutation carriers&#x02014;including asymptomatic carriers, individuals with classic DOPA-responsive dystonia and cases with adult-onset parkinsonism&#x02014;will give way to important understandings of the pathogenesis of <italic>GCH1</italic>&#x02013;associated Parkinson&#x02019;s disease.</p><sec><title>Funding</title><p>This study was supported by the <funding-source>Wellcome Trust/Medical Research Council (MRC) Joint Call in Neurodegeneration award</funding-source> (<award-id>WT089698</award-id>) to the UK Parkinson&#x02019;s Disease Consortium whose members are from the <funding-source>UCL/Institute of Neurology</funding-source>, the <funding-source>University of Sheffield</funding-source>, and the <funding-source>MRC Protein Phosphorylation Unit at the University of Dundee</funding-source>. This project was also supported by the <funding-source>National Institute for Health Research University College London Hospitals Biomedical Research Centre</funding-source> and the <funding-source>Grigioni Foundation for Parkinson Disease</funding-source>.</p></sec></body><back><ref-list><title>References</title><ref id="awu309-B1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniades</surname><given-names>C</given-names></name><name><surname>Cunnington</surname><given-names>C</given-names></name><name><surname>Antonopoulos</surname><given-names>A</given-names></name><name><surname>Neville</surname><given-names>M</given-names></name><name><surname>Margaritis</surname><given-names>M</given-names></name><name><surname>Demosthenous</surname><given-names>M</given-names></name><etal/></person-group><article-title>Induction of vascular GTP-cyclohydrolase I and endogenous tetrahydrobiopterin synthesis protect against inflammation-induced endothelial dysfunction in human atherosclerosis</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>1860</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">21969008</pub-id></element-citation></ref><ref id="awu309-B2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniades</surname><given-names>C</given-names></name><name><surname>Shirodaria</surname><given-names>C</given-names></name><name><surname>Van Assche</surname><given-names>T</given-names></name><name><surname>Cunnington</surname><given-names>C</given-names></name><name><surname>Tegeder</surname><given-names>I</given-names></name><name><surname>Lotsch</surname><given-names>J</given-names></name><etal/></person-group><article-title>GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>158</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">18598896</pub-id></element-citation></ref><ref id="awu309-B3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DD</given-names></name><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Xie</surname><given-names>JB</given-names></name><name><surname>Shu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tetrahydrobiopterin regulation of eNOS redox function</article-title><source>Curr Pharm Design</source><year>2014</year><volume>20</volume><fpage>3554</fpage><lpage>62</lpage></element-citation></ref><ref id="awu309-B19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Kish</surname><given-names>SJ</given-names></name></person-group><article-title>Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>e351</fpage></element-citation></ref><ref id="awu309-B4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Nygaard</surname><given-names>TG</given-names></name><name><surname>Gutlich</surname><given-names>M</given-names></name><name><surname>Rajput</surname><given-names>AH</given-names></name><name><surname>Pifl</surname><given-names>C</given-names></name><name><surname>DiStefano</surname><given-names>L</given-names></name><etal/></person-group><article-title>Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>1032</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10496263</pub-id></element-citation></ref><ref id="awu309-B5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>WR</given-names></name><name><surname>Narabayashi</surname><given-names>H</given-names></name><name><surname>Yokochi</surname><given-names>M</given-names></name><name><surname>Iizuka</surname><given-names>R</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>New pathologic observations in juvenile onset parkinsonism with dystonia</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>820</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">2046923</pub-id></element-citation></ref><ref id="awu309-B6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotzsch</surname><given-names>H</given-names></name><name><surname>Pizzolato</surname><given-names>GP</given-names></name><name><surname>Ghika</surname><given-names>J</given-names></name><name><surname>Schorderet</surname><given-names>D</given-names></name><name><surname>Vingerhoets</surname><given-names>FJ</given-names></name><name><surname>Landis</surname><given-names>T</given-names></name><etal/></person-group><article-title>Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>1839</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">12084887</pub-id></element-citation></ref><ref id="awu309-B20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guella</surname><given-names>I</given-names></name><name><surname>Sherman</surname><given-names>HE</given-names></name><name><surname>Appel-Cresswell</surname><given-names>S</given-names></name><name><surname>Rajput</surname><given-names>A</given-names></name><name><surname>Rajput</surname><given-names>AH</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name></person-group><article-title>Parkinson&#x02019;s disease in GTP cyclohydrolase 1 mutation carriers</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>e349</fpage></element-citation></ref><ref id="awu309-B7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>BS</given-names></name><name><surname>Jeong</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Chang</surname><given-names>YS</given-names></name><name><surname>Song</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia</article-title><source>Ann Neurol</source><year>1998</year><volume>43</volume><fpage>792</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">9629849</pub-id></element-citation></ref><ref id="awu309-B8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JH</given-names></name><name><surname>Kang</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>HK</given-names></name><name><surname>Koh</surname><given-names>YS</given-names></name><name><surname>Im</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name></person-group><article-title>A novel missense mutation of the GTP cyclohydrolase I gene in a Korean family with hereditary progressive dystonia/dopa-responsive dystonia</article-title><source>Brain Dev</source><year>2004</year><volume>26</volume><fpage>287</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15165667</pub-id></element-citation></ref><ref id="awu309-B9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mencacci</surname><given-names>NE</given-names></name><name><surname>Isaias</surname><given-names>IU</given-names></name><name><surname>Reich</surname><given-names>MM</given-names></name><name><surname>Ganos</surname><given-names>C</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Polke</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Parkinson's disease in GTP cyclohydrolase 1 mutation carriers</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>2480</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">24993959</pub-id></element-citation></ref><ref id="awu309-B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Lill</surname><given-names>CM</given-names></name><name><surname>Do</surname><given-names>CB</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><etal/></person-group><article-title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease</article-title><source>Nat Genet</source><year>2014</year><volume>46</volume><fpage>989</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">25064009</pub-id></element-citation></ref><ref id="awu309-B11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygaard</surname><given-names>TG</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Heiman</surname><given-names>GA</given-names></name><name><surname>Snow</surname><given-names>BJ</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name></person-group><article-title>Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia</article-title><source>Ann Neurol</source><year>1992</year><volume>32</volume><fpage>603</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1449240</pub-id></element-citation></ref><ref id="awu309-B18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>BJ</given-names></name><name><surname>Crabtree</surname><given-names>MJ</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name></person-group><article-title>Parkinson&#x02019;s disease in GTP cyclohydrolase 1 mutation carriers</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>e348</fpage></element-citation></ref><ref id="awu309-B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>BJ</given-names></name><name><surname>Lourenco-Venda</surname><given-names>LL</given-names></name><name><surname>Crabtree</surname><given-names>MJ</given-names></name><name><surname>Hale</surname><given-names>AB</given-names></name><name><surname>Channon</surname><given-names>KM</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name></person-group><article-title>&#x003b1;-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease</article-title><source>Free Radic Biol Med</source><year>2014</year><volume>67</volume><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">24148766</pub-id></element-citation></ref><ref id="awu309-B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawle</surname><given-names>GV</given-names></name><name><surname>Leenders</surname><given-names>KL</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Harwood</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Frackowiak</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Dopa-responsive dystonia: [18F]dopa positron emission tomography</article-title><source>Ann Neurol</source><year>1991</year><volume>30</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">1681782</pub-id></element-citation></ref><ref id="awu309-B14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segawa</surname><given-names>M</given-names></name><name><surname>Nomura</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name></person-group><article-title>Dopa-responsive dystonia is caused by particular impairment of nigrostriatal dopamine neurons different from those involved in Parkinson disease: evidence observed in studies on Segawa disease</article-title><source>Neuropediatrics</source><year>2013</year><volume>44</volume><fpage>61</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">23468278</pub-id></element-citation></ref><ref id="awu309-B15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segawa</surname><given-names>M</given-names></name><name><surname>Nomura</surname><given-names>Y</given-names></name><name><surname>Yukishita</surname><given-names>S</given-names></name><name><surname>Nishiyama</surname><given-names>N</given-names></name><name><surname>Yokochi</surname><given-names>M</given-names></name></person-group><article-title>Is phenotypic variation of hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) caused by the difference of the locus of mutation on the GTP cyclohydrolase 1 (GCH-1) gene?</article-title><source>Adv Neurol</source><year>2004</year><volume>94</volume><fpage>217</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">14509676</pub-id></element-citation></ref><ref id="awu309-B16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>BJ</given-names></name><name><surname>Nygaard</surname><given-names>TG</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name></person-group><article-title>Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism</article-title><source>Ann Neurol</source><year>1993</year><volume>34</volume><fpage>733</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8239569</pub-id></element-citation></ref><ref id="awu309-B17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadic</surname><given-names>V</given-names></name><name><surname>Kasten</surname><given-names>M</given-names></name><name><surname>Bruggemann</surname><given-names>N</given-names></name><name><surname>Stiller</surname><given-names>S</given-names></name><name><surname>Hagenah</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name></person-group><article-title>Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>1558</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">22986512</pub-id></element-citation></ref><ref id="awu309-B21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terbeek</surname><given-names>J</given-names></name><name><surname>Hermans</surname><given-names>S</given-names></name><name><surname>Laere</surname><given-names>KV</given-names></name><name><surname>Vandenberghe</surname><given-names>W</given-names></name></person-group><article-title>Parkinson&#x02019;s disease in GTP cyclohydrolase 1 mutation carriers</article-title><source>Brain</source><year>2015</year><volume>138</volume><fpage>e350</fpage></element-citation></ref></ref-list></back></article>